ImmunocoreSEVERAL: investment, 202101 financing round Series C $75m incl funds + accounts managed by BlackRock - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal
Summary
Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the completion of a $75.0 million Series C private financing round. The proceeds will enable Immunocore to further expand and accelerate its growing clinical stage pipeline of ImmTAX (Immune mobilising monoclonal TCRs Against Cancer, Infectious Diseases and Autoimmune) molecules, including its lead program tebentafusp (IMCgp100). [3],[4],[5] Up to 50% of people with uveal melanoma will eventually develop metastatic disease.1,2 When the cancer spreads beyond the eye, only approximately half of patients will survive for one year. "Press Release: Zelluna Immunotherapy Appoints Dr Bent Jakobsen, a Pioneer of TCR Therapeutics, to the Board of Directors". "Press Release: Immunocore Appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer".